Is NCT02593760 results overdue?

Yes — results are overdue. Primary completion was 2017-03-29; the FDAAA-801 reporting deadline (2018-03-29) passed 3006 days ago and no results are posted on ClinicalTrials.gov.

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

NCT ID	NCT02593760 ↗
Sponsor	Hoffmann-La Roche (INDUSTRY)
Phase	PHASE1
Status	COMPLETED
Primary completion	2017-03-29 (ACTUAL)
Reporting deadline	2018-03-29 (completion + 365d)
Days overdue	3006
Results posted	No — check results tab ↗
FDA-regulated	drug: yes, device: no
Provenance	Flagged overdue on 2026-06-21 · SHA-256 `8bdf064d643b2691…` (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02593760. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.